OKYO Pharma (OKYO Pharma) Days Payable : 0.00 (As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Days Payable?

OKYO Pharma's average Accounts Payable for the six months ended in Mar. 2023 was $1.96 Mil. OKYO Pharma's Cost of Goods Sold for the six months ended in Mar. 2023 was $0.00 Mil.

The historical rank and industry rank for OKYO Pharma's Days Payable or its related term are showing as below:

OKYO's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.145
* Ranked among companies with meaningful Days Payable only.

OKYO Pharma's Days Payable stayed the same from Mar. 2022 (0.00) to Mar. 2023 (0.00).

OKYO Pharma Days Payable Historical Data

The historical data trend for OKYO Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma Days Payable Chart

OKYO Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Days Payable

Get a 7-Day Free Trial

OKYO Pharma Semi-Annual Data
	Sep13	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of OKYO Pharma's Days Payable

For the Biotechnology subindustry, OKYO Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OKYO Pharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's Days Payable falls into.

OKYO Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

OKYO Pharma's Days Payable for the fiscal year that ended in Mar. 2023 is calculated as

	Days Payable (A: Mar. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Mar. 2022 )	+	Accounts Payable (A: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (A: Mar. 2023 )	*	Days in Period
=	( (0.742	+	2.388)	/	2 )	/	0	*	365
=	1.565					/	0	*	365
=	N/A

OKYO Pharma's Days Payable for the quarter that ended in Mar. 2023 is calculated as:

	Days Payable (Q: Mar. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2022 )	+	Accounts Payable (Q: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2023 )	*	Days in Period
=	( (1.523	+	2.388)	/	2 )	/	0	*	365 / 2
=	1.9555					/	0	*	365 / 2
=	N/A

OKYO Pharma Days Payable Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

OKYO Pharma (OKYO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

OK10:Germany

Address

14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ

Website

https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Executives

John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: Chief Executive Officer
Gabriele M Cerrone	director, 10 percent owner, officer: Executive Chairman	265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer	director	C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon	director	PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah	officer: Chief Financial Officer	55 PARK LANE, LONDON X0 W1K 1NA